Advanced Accelerator Applications, of Saint-Genis-Pouilly, France, said it received FDA and EMA orphan drug designation status for its radiopharmaceutical, Gallium-68 DOTATATE for use as a diagnostic agent for the management of gastroentero-pancreatic neuroendocrine tumors (GEP-NETs).